StoneCalibre seals Anatrace deal

StoneCalibre has completed the acquisition of Anatrace, part of Affymetrix. Headquartered in Maumee, Ohio, Anatrace is a specialized developer, manufacturer and global distributor of unique, high purity detergents and synthetic lipids for use in membrane protein studies.


StoneCalibre today announced the completion of the acquisition of Anatrace, a part of Affymetrix, Inc. (NASDAQ: AFFX). Headquartered in Maumee, Ohio, Anatrace is a highly specialized developer, manufacturer and global distributor of unique, high purity detergents and synthetic lipids for use in membrane protein studies.

Established in 1985, Anatrace has built the broadest portfolio of detergents and lipids available in the marketplace with a core competency of developing and manufacturing creative solutions for stabilizing and solubilizing macromolecules.

“Anatrace is a high quality company offering a value-add product that is mission critical to its customer base,” said Brian Wall, Founder and Chief Executive Officer of StoneCalibre. “We are confident that as a standalone company, Anatrace will continue to build on its tradition of collaborating with its global customer base to help answer critical questions in the advancement of important studies across multiple scientific fields including cancer research.”

“StoneCalibre has been a great partner for us through this process,” said Frank Witney, Chief Executive Officer of Affymetrix. “Their corporate carve-out experience and ability to offer speed and certainty around the sale process were critical factors for us. We feel that StoneCalibre will provide a great long-term home for Anatrace and its devoted employee base.”

Ben Travis, the newly appointed CEO of Anatrace, expressed his enthusiasm for partnering with StoneCalibre. “Anatrace’s passion for detergents and lipids, combined with StoneCalibre’s strategic and financial support, will help drive the company to higher levels of excellence and allow us to capitalize on future growth opportunities.”

Anatrace is StoneCalibre’s second acquisition in the last five months. The terms of the transaction were not disclosed. EMA Partners acted as the exclusive financial advisor to Affymetrix.

About StoneCalibre

Headquartered in Century City, CA, StoneCalibre is a privately funded investment firm specializing in the acquisition of lower middle market companies. Founded by Brian Wall in 2012, StoneCalibre is focused on making investments in both special situations and quality long-term capital investment opportunities. For more information please visit our website at

About Affymetrix

Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of bench-top research into clinical and routine use for human health and wellness.
Affymetrix strives to provide leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest for answers toward using biology for a better world.

More than 2,300 microarray systems have been shipped around the world and more than 48,000 peer-reviewed papers have been published citing these technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna and Singapore. The Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America.

For more information please contact:

Nick Matzke
Business Development
StoneCalibre, LLC
Phone: (310) 774-0376
Fax: (310) 427-7448